Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Equity Average (2019 - 2025)

Eton Pharmaceuticals' Equity Average history spans 7 years, with the latest figure at $23.5 million for Q3 2025.

  • For Q3 2025, Equity Average rose 59.93% year-over-year to $23.5 million; the TTM value through Sep 2025 reached $23.5 million, up 59.93%, while the annual FY2024 figure was $20.0 million, 39.75% up from the prior year.
  • Equity Average for Q3 2025 was $23.5 million at Eton Pharmaceuticals, down from $24.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $24.4 million in Q1 2025 and bottomed at $12.1 million in Q4 2022.
  • The 5-year median for Equity Average is $16.2 million (2023), against an average of $17.1 million.
  • The largest annual shift saw Equity Average skyrocketed 332.31% in 2021 before it tumbled 37.04% in 2022.
  • A 5-year view of Equity Average shows it stood at $16.6 million in 2021, then dropped by 27.13% to $12.1 million in 2022, then soared by 33.43% to $16.2 million in 2023, then increased by 24.84% to $20.2 million in 2024, then rose by 16.53% to $23.5 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Equity Average are $23.5 million (Q3 2025), $24.2 million (Q2 2025), and $24.4 million (Q1 2025).